India Advances Anti-Dumping Probe on Key Tuberculosis Drug Imports from China and Thailand

Spread the Message

Read Time:4 Minute, 19 Second

India has advanced an anti-dumping investigation into imports of Ethambutol Hydrochloride from China and Thailand, a critical pharmaceutical ingredient used in tuberculosis (TB) treatment. This probe, initiated by the Directorate General of Trade Remedies (DGTR) following a complaint by domestic drugmaker Lupin Ltd, targets alleged unfairly low-priced imports that are said to harm Indian pharmaceutical manufacturers. The investigation covers imports during April 2024 to March 2025 and may lead to anti-dumping duties if the findings confirm injury to domestic industry.

Key Findings and Context

Ethambutol Hydrochloride is a key active pharmaceutical ingredient in anti-tuberculosis drugs. TB, caused by the bacterium Mycobacterium tuberculosis, remains a major public health challenge globally and in India. Ethambutol disrupts the synthesis of arabinogalactan, an essential polymer in the mycobacterial cell wall, thereby killing active TB bacteria. It is commonly used in combination with other first-line TB drugs such as Isoniazid and Rifampicin to enhance effectiveness and reduce resistance development.

The DGTR’s investigation was prompted by Lupin Ltd’s complaint that imports of Ethambutol from China and Thailand are being “dumped” — sold at prices below fair market value — which allegedly undercuts domestic producers, distorts market pricing, and risks the viability of Indian pharmaceutical manufacturing.

India has been increasingly vigilant in protecting its domestic industries from unfair trade practices. This probe is part of a wider effort by the DGTR, which in September 2025 also initiated numerous anti-dumping and countervailing investigations across sectors such as steel, solar panels, and chemicals, targeting imports mainly from China, Thailand, and South Korea.

Expert Perspectives and Implications

Dr. Anil Mehta, a pharmaceutical policy expert not involved in this case, explains: “Anti-dumping investigations are important mechanisms for ensuring a level playing field. While keeping drug prices affordable is critical for public health, unfair pricing that drives local manufacturers out of business can disrupt supply chains and long-term access to essential medicines.” He notes the balance between preventing dumping and ensuring that drug costs remain accessible for patients is delicate and must be carefully managed.

Ethambutol is vital in TB treatment regimens supported by the World Health Organization (WHO) and the Indian TB control programs. Any disruption in domestic production capabilities could affect the medicine’s availability and affordability, which has public health implications given India’s high TB burden.

The Importance of Fair Trade and Drug Supply Security

India’s pharmaceutical industry is a global hub for affordable generic drugs, and domestic production capacity supports national health programs and exports. Protecting this sector against unfairly priced imports that can cause market injury is a priority to sustain local industry, preserve employment, and maintain drug supply security.

The DGTR’s investigation will assess import pricing, the extent of market injury, and industry health before recommending any anti-dumping duties. If duties are imposed, they could increase costs of imported Ethambutol ingredients, potentially impacting drug manufacturers reliant on imports for their supply chain.

Balancing Affordability and Industry Health

While anti-dumping duties might increase costs temporarily, they could also encourage local pharmaceutical companies to invest in expanded or improved production of Ethambutol, thereby ensuring sustainable supply in the longer term.

Some critics argue that anti-dumping measures can raise prices and limit competition. However, Indian authorities emphasize that the probe’s goal is not to restrict imports indiscriminately, but to address unfair pricing practices that harm the domestic sector and ultimately impact patient access by destabilizing the market.

Statistical and Regulatory Context

The DGTR investigation period covers April 2024 to March 2025, a year-long review designed to provide comprehensive evidence on import patterns and domestic industry effects. India’s trade remedy laws mandate such probes to safeguard domestic businesses from material injury caused by dumped or subsidized imports.

The increasing number of anti-dumping cases initiated by DGTR in 2025 reflects a broader policy focus on protecting key domestic industries across multiple sectors, including pharmaceuticals.

Practical Takeaways for Health Consumers

For patients and healthcare providers, this investigation underscores the importance of a resilient domestic pharmaceutical industry that can produce essential medications reliably and affordably. Ethambutol is a crucial drug in TB treatment regimens, and its availability must be preserved to ensure effective disease control.

Consumers should understand that while trade measures might affect drug pricing or availability in the short term, such actions aim to sustain long-term drug supply security and industry health, which benefit public health overall.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.